2/2 Thanks to the team

1/2 The Uromigos Score for MIBC. Neoadjuvant chemo & ICIs strongly supported (irrespective of PD-L1 status). Perioperative durva scores higher than adjuvant nivo in cisplatin eligibles (2.9 vs 2.1). TMT appears a reasonable alternative to surgery (1.9). Nivo and Pembro have

2/2 many thanks to global contributors. We await other perioperative IO trials including EVP & DTEV which is likely to change everything.

🔵 #UromigosScore para MIBC: Respaldo a QT+ICIs neoadyuvante (indep PD-L1). Durva periop. > Nivo adyuvante en cis-elegible (2.9 vs 2.1). TMT alternativa razonable (1.9). Nivo/Pembro similares y opción en no elegibles.

🚨 New episode alert! Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well. 🎙️ GU Oncology Now: buff.ly/N5cAT6F 🍎 Apple Podcasts:

POTOMAC trial- Durvalumab + BCG shows positive results for DFS in high-risk NMIBC vs BCG alone. sasanlimab (CREST) also had an EFS advantage here: HR 0.68. Consistent results in early disease is compelling. IO tox is relevant in risk/benefit ratio. astrazeneca.com/media-centre/p…

1/N Uromigos Tweet of the Month!! The Uromigos Score for Advanced Prostate Cancer We polled 24 prostate cancer experts from 13 countries regarding the value of different treatment options in various advanced prostate cancer disease states. 🇺🇸🇦🇺🇧🇷🇩🇪🇮🇹🇦🇹🇪🇸🇨🇭🇯🇵🇬🇧🇸🇬🇧🇪🇹🇷 Podcast

3/N Take Home Points in Metastatic Castrate Resistant Prostate Cancer (mCRPC) as first line therapy after ADT + ARPI with no prior docetaxel: · Docetaxel scores high independent of HRR status · PARPi monotherapy favored over all other options including PARPi + ARPI in BRCA

4/N

🔐(1/4) CPRCm según el #Uromigoscore: 1️⃣ línea tras TDA + ARPI: ✅ Docetaxel recibe puntuaciones altas en todos los subgrupos moleculares, independientemente del estado HRR. ❌ Cambiar de ARPI: estrategia poco valorada. Uromigos OncoAlert

🆕ESMO guideline podcast🎧: Annals of Oncology Editor-in-Chief Tom Powles discusses the ESMO ESMO Clinical Practice Guideline for hepatocellular carcinoma with Arndt Vogel tinyurl.com/msfbh7fe For the full Clinical Practice Guideline see doi.org/10.1016/j.anno…

🚨 New episode alert! silke gillessen and Christopher Sweeney, MBBS join us to discuss our latest 'Uromigos Score' in which experts score the value of treatments for advanced prostate cancer. Expect some interesting themes and insights. 🎙️ GU Oncology Now: buff.ly/GzQAw1J 🍎

Published! Previliged to be a Part of SUNNIFORCAST! World largest ranomized trial on #non-ccRCC #kidney cancer deiven by Academia #MHH

🆕article in press: Pembrolizumab plus enzalutamide and androgen deprivation therapy vs placebo plus enzalutamide and androgen deprivation therapy for mHSPC: the randomized, double-blind, phase III KEYNOTE-991 study Christian Gratzke doi.org/10.1016/j.anno…

Our International Clinical Trials Day event is happening now! Organised by our @bartsecmc patient group. You are welcome to pop in to West Wing and listen to our speakers. Up first is Tom Powles talking all about personalised cancer vaccines 💉🔬

Thank you to everyone who came and took part in our International Clinical Trials Day event! If you are interested in keeping up to date with our events, please send us message or email [email protected] ✨ ECMC Network (@ecmc-uk.bsky.social) Barts Health